Granzyme B PET Imaging Stratifies Immune Checkpoint Inhibitor Response in Hepatocellular Carcinoma

Figure 2

(a) Maximum intensity projection images depicting [¹⁸F]AlF-NOTA-GZP tumour retention. Yellow dotted areas indicate the HEPA 1-6 tumour border. Mice were injected with [¹⁸F]AlF-NOTA-GZP (~10 MBq intravenously) and static images acquired from 60-80 mins postinjection. (b) Graph showing differences in [¹⁸F]AlF-NOTA-GZP tumour retention from each treatment arm. [¹⁸F]AlF-NOTA-GZP tumour retention was significantly increased in αPD-1, αCTLA4 and combined treatment arms when compared to treated nonresponders (TNR, mice/group; ; comparing TR to TNR; data shown as ). (c) Individual values for [¹⁸F]AlF-NOTA-GZP tumour retention in TRs and TNRs (, data shown as individual %ID/g).

(a)

(b)

(c)